AG-120 (Ivosidenib): Mutant IDH1 Inhibition and 2-HG Reduction

Executive Summary: AG-120 (Ivosidenib) inhibits mutant IDH1, reducing intracellular 2-hydroxyglutarate (2-HG) and restoring normal cell differentiation in acute myeloid leukemia (AML) and solid tumor models (product_spec). This small molecule shows strong selectivity for mutant over wild-type IDH1, with in vitro and ex vivo assays confirming its role in decreasing 2-HG and promoting erythropoietin-induced myeloid differentiation (workflow_recommendation). Clinical trials document disease stabilization in subsets of IDH1-mutant cancers (product_spec). Recent research highlights dependencies on CD44-mediated metabolic rewiring in IDH-mutant leukemia, suggesting combined pathway targeting (paper). AG-120 (Ivosidenib), available from APExBIO, offers a purity of ≥98% and robust solubility in DMSO and ethanol (product_spec).

Biological Rationale

Isocitrate dehydrogenase 1 (IDH1) is a cytoplasmic enzyme catalyzing the conversion of isocitrate to α-ketoglutarate (α-KG), a key step in cellular metabolism. Mutations in IDH1, particularly at residue R132 (e.g., R132H), impart a neomorphic activity: the reduction of α-KG to the oncometabolite (R)-2-hydroxyglutarate (2-HG) using NADPH as a cofactor (paper). Accumulation of 2-HG is a defining feature of IDH1-mutant malignancies such as AML and gliomas. 2-HG inhibits α-KG-dependent dioxygenases, altering epigenetic regulation, DNA damage repair, and cell differentiation, thereby promoting tumorigenesis. CD44, a cell adhesion molecule, is upregulated in IDH-mutant leukemia, supporting metabolic rewiring to sustain NADPH for 2-HG production (paper).

Mechanism of Action of AG-120 (Ivosidenib), mutant IDH1 inhibitor

AG-120 (Ivosidenib) is a potent, selective, orally bioavailable inhibitor of mutant IDH1. It binds allosterically to the mutant enzyme, blocking its neomorphic activity and reducing the NADPH-dependent conversion of α-KG to 2-HG (product_spec). This action restores normal cellular metabolic flux and allows for endogenous differentiation signals, such as erythropoietin, to drive myeloid maturation. AG-120 demonstrates minimal activity against wild-type IDH1, IDH2, or other dehydrogenases, supporting its selectivity as a targeted small molecule cancer therapeutic (workflow_recommendation).

Evidence & Benchmarks

• AG-120 reduces intracellular 2-HG levels in TF-1 IDH1-R132H mutant cells in vitro, with dose-dependent efficacy (source: product_spec).
• Ex vivo application to primary AML patient samples with IDH1 mutation results in significant 2-HG reduction and induction of myeloid differentiation (source: product_spec).
• Phase I clinical trial data report disease stabilization and partial responses in IDH1-mutant solid tumors, including intrahepatic cholangiocarcinoma and chondrosarcoma (source: product_spec).
• CD44 is indispensable for sustaining high 2-HG output in IDH-mutant leukemia, suggesting that AG-120 efficacy may be enhanced by targeting CD44-mediated metabolic pathways (source: paper).
• Resistance to AG-120 in patients can arise via second-site mutations affecting the dimer interface or NADPH binding, and by isoform switching to IDH2 (source: paper).

This article advances the discussion in "Metabolic Dependencies in IDH1-Mutant Leukemia: AG-120 (Ivosidenib) and the CD44 Axis" by providing detailed molecular benchmarks and protocol parameters for laboratory applications.

For a practical guide to integrating AG-120 in mutant IDH1 workflows, see "Applied Workflows with AG-120 (Ivosidenib) in IDH1-Mutant AML", which this article extends by critically evaluating clinical resistance mechanisms and metabolic dependencies.

Applications, Limits & Misconceptions

AG-120 (Ivosidenib) is validated for the treatment and study of IDH1-mutant AML and select solid tumors. It is most effective where IDH1 mutations are the primary driver of 2-HG accumulation. The compound’s selectivity reduces the risk of off-target effects seen with less specific inhibitors. However, its efficacy is limited by acquired resistance in some patients, often due to secondary mutations or metabolic adaptation.

Common Pitfalls or Misconceptions

• AG-120 does not inhibit wild-type IDH1 or IDH2, thus it is ineffective in cancers lacking IDH1 mutations (source: product_spec).
• Reduction of 2-HG alone does not guarantee clinical remission; co-occurring mutations may blunt therapeutic benefit (source: paper).
• Long-term storage of AG-120 solutions at room temperature can degrade compound integrity (source: product_spec).
• AG-120 is insoluble in water; improper solvent selection may cause precipitation and loss of activity (source: product_spec).
• Clinical resistance may occur through dimer interface mutations or isoform switching; monotherapy may be insufficient for durable responses (source: paper).

Workflow Integration & Parameters

Protocol Parameters

• Cellular differentiation assay | 0.1–10 μM AG-120 | TF-1 IDH1-R132H cells | Demonstrates dose-dependent 2-HG reduction and erythropoietin-induced differentiation | product_spec
• Solubility test | ≥58.3 mg/mL in DMSO; ≥63.3 mg/mL in ethanol | Compound preparation for cell-based and biochemical assays | Ensures maximal compound availability and stability | product_spec
• Storage conditions | -20°C (solid); avoid long-term storage of solutions | All formats | Preserves compound purity (≥98%) and activity | product_spec
• Ex vivo AML patient sample assay | 1–5 μM AG-120 | Human primary AML cells with IDH1 mutation | Validates 2-HG reduction and myeloid differentiation | workflow_recommendation

Conclusion & Outlook

AG-120 (Ivosidenib) from APExBIO represents a robust tool for probing and modulating mutant IDH1-driven metabolic rewiring, particularly for AML and select solid tumors. Evidence supports its ability to lower 2-HG and restore differentiation, but clinical resistance highlights the need for combination strategies (e.g., with CD44-targeting agents) (paper). Ongoing research should prioritize integrating metabolic and genetic profiling to optimize AG-120-based regimens. For further technical details and troubleshooting, the B7805 kit manual is essential (product_spec).